WO1998020864A3 - Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives - Google Patents
Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives Download PDFInfo
- Publication number
- WO1998020864A3 WO1998020864A3 PCT/EP1997/006323 EP9706323W WO9820864A3 WO 1998020864 A3 WO1998020864 A3 WO 1998020864A3 EP 9706323 W EP9706323 W EP 9706323W WO 9820864 A3 WO9820864 A3 WO 9820864A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prevention
- treatment
- neurodegenerative diseases
- steroidal antiinflammatory
- selected non
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT96MI002356A ITMI962356A1 (it) | 1996-11-13 | 1996-11-13 | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
ITMI96A002356 | 1996-11-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998020864A2 WO1998020864A2 (fr) | 1998-05-22 |
WO1998020864A9 WO1998020864A9 (fr) | 1998-08-27 |
WO1998020864A3 true WO1998020864A3 (fr) | 1998-10-15 |
Family
ID=11375202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/006323 WO1998020864A2 (fr) | 1996-11-13 | 1997-11-13 | Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITMI962356A1 (fr) |
WO (1) | WO1998020864A2 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3641597A (en) | 1996-06-21 | 1998-01-07 | Advanced Research And Technology Institute, Inc. | Methods and compositions comprising r-ibuprofen |
US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
JP2002519373A (ja) | 1998-07-02 | 2002-07-02 | エーザイ株式会社 | 製薬組成物及びそれらの使用 |
IT1302898B1 (it) * | 1998-12-03 | 2000-10-10 | Medosan Ricerca Srl | Uso di amtolmetine guacil per la produzione di farmaci ad effettoantiinfiammatorio nelle infiammazioni intestinali. |
DE60028787T2 (de) * | 1999-08-10 | 2007-06-06 | Uab Research Foundation, Birmingham | Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten |
KR100417623B1 (ko) * | 2000-03-28 | 2004-02-05 | 주식회사 뉴로테크 | 뇌질환 예방 및 치료용 조성물 |
RU2303452C2 (ru) * | 2000-07-20 | 2007-07-27 | Леурас Ас | Применение ингибиторов сох-2 для предупреждения иммунодефицита |
DE10103506A1 (de) * | 2001-01-26 | 2002-08-14 | Ingo S Neu | Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose |
EP1371366A1 (fr) * | 2002-05-17 | 2003-12-17 | Faust Pharmaceuticals | Méthode de prévention et de traitement de troubles neurologiques |
WO2003097024A1 (fr) * | 2002-05-17 | 2003-11-27 | Faust Pharmaceuticals | Methodes de prevention et/ou de traitement de troubles neurologiques |
JP4743382B2 (ja) | 2002-06-06 | 2011-08-10 | 株式会社医薬分子設計研究所 | O−置換ヒドロキシアリール誘導体 |
EA011707B1 (ru) * | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
AU2003272068A1 (en) * | 2002-10-21 | 2004-05-04 | Ramot At Tel Aviv University Ltd. | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
US7265245B2 (en) * | 2003-10-08 | 2007-09-04 | Innovaprotean, S.L | Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils |
GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
CA2564868C (fr) | 2004-04-28 | 2013-11-26 | Molecules For Health, Inc. | Methodes permettant de traiter ou de prevenir la restenose et d'autres troubles vasculaires proliferants |
US9216966B2 (en) | 2004-10-04 | 2015-12-22 | John Manfredi | Compounds for Alzheimer's disease |
JP2008515805A (ja) * | 2004-10-04 | 2008-05-15 | ミリアド ジェネティクス, インコーポレイテッド | アルツハイマー病のための化合物 |
EP1645288A1 (fr) * | 2004-10-07 | 2006-04-12 | CTG Pharma S.r.l. | Nouveaux régulateurs des facteurs de transcription nucleaire |
CA2648652A1 (fr) * | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Composes pour le traitement de maladies et de troubles |
EP2030615A3 (fr) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Inhibiteurs de la ribonucleotide reductase pour leur utilisation dans le traitement ou la prévention de maladies neuro-inflammatoires ou auto-immunes |
CN101868443A (zh) | 2007-09-20 | 2010-10-20 | 特拉维夫大学拉莫特有限公司 | N-苯基邻氨基苯甲酸衍生物及其用途 |
CA2710318A1 (fr) * | 2007-12-21 | 2009-07-09 | Paz Arzneimittel-Entwicklungsgesellscaft Mbh | Medicament, sa fabrication et son utilisation pour le traitement de neuropathies douloureuses |
WO2009138437A1 (fr) * | 2008-05-13 | 2009-11-19 | Genmedica Therapeutics Sl | Conjugués de salicylés utiles pour le traitement de troubles métaboliques |
CN102816082B (zh) * | 2010-01-29 | 2015-03-11 | 浙江大学 | 苯甲酰胺类衍生物及制备方法和应用 |
CN101817761B (zh) * | 2010-01-29 | 2014-06-25 | 浙江大学 | 苯甲酸酯类衍生物及制备方法和应用 |
JP6328146B2 (ja) | 2013-02-01 | 2018-05-23 | グリアロジクス・インコーポレイテッドGlialogix, Inc. | 神経変性およびその他の疾患の治療用組成物および方法 |
US20150086616A1 (en) * | 2013-09-20 | 2015-03-26 | Steven Lehrer | Method for the prevention and treatment of alzheimer's disease |
GB201416017D0 (en) | 2014-09-10 | 2014-10-22 | New Royal Holloway & Bedford | An Anticonvulsant Compound |
US20170143681A1 (en) | 2015-11-02 | 2017-05-25 | Apkarian Technologies Llc | Methods and compositions for treating pain |
JP6962572B2 (ja) * | 2016-03-18 | 2021-11-05 | 学校法人同志社 | 2,4−ジアミノフェノール誘導体、及び、タウ及び/又はアミロイドβの凝集阻害剤 |
WO2022243507A1 (fr) * | 2021-05-20 | 2022-11-24 | Institut Du Cerveau Et De La Moelle Epiniere | Tenoxicam pour le traitement de protéinopathies du système nerveux central |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024115A1 (fr) * | 1991-04-23 | 1993-12-09 | The University Of British Columbia | Utilisation de substances pharmaceutiques contre la polyarthrite rhumatismale pour le traitement de la maladie d'alzheimer |
US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
WO1997044020A1 (fr) * | 1996-05-21 | 1997-11-27 | Angelini Ricerche S.P.A. Societa' Consortile | Utilisation de derives du p-aminophenol pour la preparation de compositions pharmaceutiques utiles dans le traitement de maladies neuro-degeneratives |
-
1996
- 1996-11-13 IT IT96MI002356A patent/ITMI962356A1/it not_active Application Discontinuation
-
1997
- 1997-11-13 WO PCT/EP1997/006323 patent/WO1998020864A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024115A1 (fr) * | 1991-04-23 | 1993-12-09 | The University Of British Columbia | Utilisation de substances pharmaceutiques contre la polyarthrite rhumatismale pour le traitement de la maladie d'alzheimer |
US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
WO1997044020A1 (fr) * | 1996-05-21 | 1997-11-27 | Angelini Ricerche S.P.A. Societa' Consortile | Utilisation de derives du p-aminophenol pour la preparation de compositions pharmaceutiques utiles dans le traitement de maladies neuro-degeneratives |
Non-Patent Citations (10)
Title |
---|
BREITNER J C S ET AL: "DELAYED ONSET OF ALZHEIMER'S DISEASE WITH NONSTEROIDAL ANTI.INFLAMMATORY AND HISTAMINE H2 BLOCKING DRUGS", NEUROBIOLOGY OF AGING, vol. 16, no. 4, 1995, pages 523 - 530, XP002041828 * |
C.B. ANDERSON ET AL.: "DIFLUNISAL IN IDIOPATHIC PARKINSON'S DISEASE", NEUROLOGY, vol. 34, no. 3, 1984, pages 400, XP002062729 * |
I.S. NEU: "BEHANDLUNG DER MULTIPLEN SKLEROSE MIT SULFASALAZIN", NERVENHEILKUNDE, vol. 13, no. 2, 1994, pages 97 - 98, XP002062728 * |
J.C.S. BREITNER: "WHY ANTI-INFLAMMATORY DRUGS MAY BE A TREATMENT FOR ALZHEIMER'S DISEASE", NEUROTOXICOLOGY, vol. 17, no. 3-4, October 1996 (1996-10-01), pages 942, XP002062730 * |
J.E.F. REYNOLDS: "MARTINDALE, THE EXTRA PHARMACOPOEIA", 1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON, XP002062731 * |
J.S. MEYER ET AL.: "RANDOMIZED CLINICAL TRIAL OF DAILY ASPIRIN THERAPY IN MULTI-INFARCT DEMENTIA", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, vol. 37, no. 6, 1989, pages 549 - 555, XP002062726 * |
M. GRILLI ET AL.: "NEUROPROTECTION BY ASPIRIN AND SODIUM SALICYLATE THROUGH BLOCKAGE OF NF-KAPPAB ACTIVATION", SCIENCE, vol. 274, 22 November 1996 (1996-11-22), pages 1383 - 1385, XP002062723 * |
M.W. RIEPE ET AL.: "ACETYLSALICYLIC ACID INCREASES TOLERANCE AGAINST HYPOXIC AND CHEMICAL HYPOXIA", STROKE, vol. 28, no. 10, October 1997 (1997-10-01), pages 2006 - 2011, XP002062724 * |
R.J. OKEN ET AL.: "ALZHEIMER DISEASE: ASPIRIN PROPHYLAXIS AND THERAPY", ALZHEIMER DISEASE AND ASSOCIATED DISORDERS, vol. 6, no. 1, 1992, pages 53 - 54, XP002062725 * |
Y. FUJITA ET AL.: "EVALUATION OF A LOW DOSE ADMINISTRATION OF ASPIRIN, DIPYRIDAMOL AND STEROID.", PARAPLEGIA, vol. 23, no. 1, 1985, pages 56 - 57, XP002062727 * |
Also Published As
Publication number | Publication date |
---|---|
ITMI962356A1 (it) | 1998-05-13 |
WO1998020864A2 (fr) | 1998-05-22 |
ITMI962356A0 (it) | 1996-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998020864A3 (fr) | Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives | |
AU1402895A (en) | Use of pla2 inhibitors as treatment for alzheimer's disease | |
WO2003047577A3 (fr) | Compositions pharmaceutiques et utilisations associees | |
IL121170A0 (en) | Compositions for the treatment of dermatological disorders | |
AU1407399A (en) | Treatment for alzheimer's disease | |
AU2830097A (en) | Therapeutic method for treatment of alzheimer's disease | |
AU698509B2 (en) | Compositions for the treatment of rheumatoid-based arthritic diseases | |
ZA977310B (en) | Transdermal propentofylline compositions for the treatment of Alzheimer's disease. | |
AU7556994A (en) | Methods for the diagnosis of alzheimer's disease | |
NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
AU3364499A (en) | Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
CA2301706A1 (fr) | Utilisation de phanquinone dans le traitement de la maladie d'alzheimer | |
AU5053296A (en) | Pharmaceutical agents for the treatment of Alzheimer's disease | |
AU1405899A (en) | Treatment for alzheimer's disease | |
AU1831195A (en) | Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders | |
AU4215499A (en) | Treatment of neurodegenerative diseases | |
EE03437B1 (et) | Benseenamiidid neurodegeneratiivsete haiguste ravimiseks | |
AU2003299101A1 (en) | Compounds for the treatment of alzheimer's disease | |
AU5854799A (en) | Novel treatment of neurodegenerative diseases | |
AU1002697A (en) | Topical compositions for the treatment of skin disease | |
AU2002300055A1 (en) | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias | |
AU2002350043A1 (en) | Hydroxy substituted amides for the treatment of alzheimer's disease | |
AU2002316622A1 (en) | Aminediols for the treatment of alzheimer's disease | |
AU2002320537A1 (en) | Diaminediols for the treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGE 4/4, DRAWINGS, REPLACED BY A NEW PAGE 4/4 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |